The safety and efficacy of selective combination therapy for BRAF V600E-mutant metastatic colorectal cancer is being evaluated in an open-label, randomized, three-arm, phase III trial51 (BEACON Colorectal cancer trial; ClinicalTrials.gov identifier: NCT02928224; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). The gene discussed is BRAF; the disease is metastatic colorectal cancer.